http://pharmaweblog.com/blog/2006/05/05/jury-awards-ariad-damages-in-lilly-patent-dispute/ Pharmaceutical and biotech science and business Thu, 28 Aug 2008 20:02:23 +0000 http://wordpress.org/?v=2.0.2 http://pharmaweblog.com/blog/2006/05/05/jury-awards-ariad-damages-in-lilly-patent-dispute/#comment-68 Wed, 11 Jul 2007 19:29:50 +0000 http://pharmaweblog.com/blog/2006/05/05/jury-awards-ariad-damages-in-lilly-patent-dispute/#comment-68 [...] I’ve been following along with the circus that is Ariad v Lilly for over a year now (see 2006 posts May 5, June 28, June 6), and, as I find it fascinating, I’m going to keep writing about it.  If patent decisions bore you, read no further.  The latest news is significant: Ariad has prevailed in a bench trial held in Massachusetts federal court.  The prior jury award, giving Ariad entitlement to 2.3% of revenues from sales of Xigris and Evista (valued at ~$65 million at the time of the award), stands for now.  Lilly has not yet commented on the Court’s decision.  At the same time Ariad was getting this bit of good news, they received word from the USPTO that the patent claims upheld by the Massachusetts Court were nullified for now.  Ariad will appeal the USPTO decision, which will take one to two years to be finally decided.  In the meantime, the award against Lilly will stand unless appealed. [...] […] I’ve been following along with the circus that is Ariad v Lilly for over a year now (see 2006 posts May 5, June 28, June 6), and, as I find it fascinating, I’m going to keep writing about it.  If patent decisions bore you, read no further.  The latest news is significant: Ariad has prevailed in a bench trial held in Massachusetts federal court.  The prior jury award, giving Ariad entitlement to 2.3% of revenues from sales of Xigris and Evista (valued at ~$65 million at the time of the award), stands for now.  Lilly has not yet commented on the Court’s decision.  At the same time Ariad was getting this bit of good news, they received word from the USPTO that the patent claims upheld by the Massachusetts Court were nullified for now.  Ariad will appeal the USPTO decision, which will take one to two years to be finally decided.  In the meantime, the award against Lilly will stand unless appealed. […]

]]>